Accendra Health, trading under the symbol ACH on the NYSE, is a company that has recently caught the attention of investors. On February 22, 2026, UBS maintained its "Buy" rating for ACH, even though it lowered the price target from $4 to $3. At that time, the stock was priced at $2.61. Accendra Health has faced challenges, but there are signs of potential growth.
The stock has been upgraded to a "Buy" rating after a period of underperformance. Currently, ACH is trading at just two times its projected free cash flow for 2027. This suggests that the stock might be undervalued, offering a potential opportunity for investors. Despite the challenges, the company is expected to overcome its hurdles.
Accendra Health is dealing with significant margin pressure and a challenging balance sheet. The net leverage is anticipated to be between 4.9 to 5 times by the end of 2026. This indicates that the company has a high level of debt compared to its earnings. However, the company is expected to manage these challenges and improve its financial position.
The year 2026 is likely to be a low point for Accendra Health due to the loss of a major contract. However, growth is expected to resume in 2027, supported by increased volumes from UnitedHealth. This partnership could provide a boost to the company's revenue and help it recover from the setbacks experienced in 2026.
Currently, ACH is priced at $2.61, with a recent price change of $0.13, reflecting a 5.24% increase. The stock has fluctuated between a low of $2.02 and a high of $2.66 during the day. Over the past year, ACH has reached a high of $10.43 and a low of $1.84. The company's market capitalization is approximately $201.87 million, with a trading volume of 1,982,366 shares.
